MoonLake Immunotherapeutics (MLTX) Accounts Payables (2020 - 2026)

MoonLake Immunotherapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $23.4 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 94.74% year-over-year to $23.4 million in Q1 2026; TTM through Mar 2026 was $23.4 million, a 94.74% increase from a year earlier, with the FY2025 full-year figure at $29.6 million, up 228.66% from the prior year.
• Accounts Payables retreated to $23.4 million in Q1 2026 per MLTX's latest filing, from $29.6 million in the prior quarter.
• Across five years, Accounts Payables topped out at $29.6 million in Q4 2025 and bottomed at $254972.0 in Q4 2022.
• The 5-year median for Accounts Payables is $4.8 million (2023), against an average of $9.4 million.
• Across the five-year window, Accounts Payables sank 83.75% in 2022 and jumped 620.74% in 2023, its largest moves.
• Year by year, Accounts Payables stood at $254972.0 in 2022, then soared by 620.74% to $1.8 million in 2023, then surged by 389.31% to $9.0 million in 2024, then surged by 228.66% to $29.6 million in 2025, then dropped by 20.89% to $23.4 million in 2026.
• Per Business Quant, the three latest MLTX Accounts Payables figures stand at $23.4 million (Q1 2026), $29.6 million (Q4 2025), and $25.3 million (Q3 2025).